Date: 2018-06-08
Type of information: Nomination
Compound: member of the board of directors
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 8, 2018, Amicus Therapeutics announced the election and appointment of the company’s President and Chief Operating Officer Bradley L. Campbell to its Board of Directors, effective immediately. In addition, Amicus announced that Donald J. Hayden, Jr. and Craig A. Wheeler were re-elected at the 2018 Annual Meeting of Stockholders. Mr. Campbell is the President and Chief Operating Officer of Amicus and leads the global commercial organization responsible for the launch of Galafold® for the treatment of Fabry Disease. In addition, he oversees the Manufacturing and Technical Operations, Market Access, and Program Management functions. Prior to joining Amicus in 2006, Bradley spent time in various commercial and business development roles at Genzyme and BMS and as a strategy consultant for Marakon Associates.
- Mr. Campbell currently serves as a member of the Board of Directors of Progenics Pharmaceuticals and is also a member of the BioNJ Board and of the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.
Financial terms:
Latest news:
Is general: Yes
